Identifying Biomarkers for Immunotherapy

For example, we set up model systems where we could control both the mutation load as well as the intratumor heterogeneity, to understand the relative contribution of each of these parameters to immune response.  We studied this question in a novel controlled mouse melanoma model that enabled us to explore the effects of intra-tumor heterogeneity (ITH) on tumor aggressiveness and immunity independent of tumor mutational burden.

Further reading:

Wolf, Y. et al. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. Cell 179, 219-235 (2019)

Kalaora, S. et al. Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. Nat Commun 11, 896 (2020)

Wolf, Y. et al. Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally. Clin Cancer Res 28, 2994-3001 (2022)

Kalaora, S. et al. Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer 22, 195-207 (2022)